中国新药杂志

钠-葡萄糖协同转运蛋白2抑制剂降糖作用外肾脏保护机制研究进展

PDF下载

唐明娟 , 李凝旭

中国新药杂志 | 综述 2021,30(14): 1289-1295

收起

中国新药杂志 |综述 2021 , 30 (14) : 1289 -1295

钠-葡萄糖协同转运蛋白2抑制剂降糖作用外肾脏保护机制研究进展

全屏

[Author(id=1322181127499002769, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=m201876025@hust.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322181127616443283, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, authorId=1322181127499002769, language=EN, stringName=Ming-juan TANG, firstName=Ming-juan, middleName=null, lastName=TANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Nephropathy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322181127712912276, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, authorId=1322181127499002769, language=CN, stringName=唐明娟, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=华中科技大学同济医学院附属梨园医院肾病内科，武汉　430077, bio={"content":"

唐明娟，女，硕士研究生，研究方向：糖尿病肾病治疗研究。E-mail：m201876025@hust.edu.cn。

"}, bioImg=null, bioContent=

唐明娟，女，硕士研究生，研究方向：糖尿病肾病治疗研究。E-mail：m201876025@hust.edu.cn。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322181127402533773, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, xref=null, ext=[AuthorCompanyExt(id=1322181127410922382, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, companyId=1322181127402533773, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Nephropathy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China), AuthorCompanyExt(id=1322181127415116687, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, companyId=1322181127402533773, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=华中科技大学同济医学院附属梨园医院肾病内科，武汉　430077)])]), Author(id=1322181127830352790, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=liningxu@hust.edu.cn, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322181127943599000, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, authorId=1322181127830352790, language=EN, stringName=Ning-xu LI, firstName=Ning-xu, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Nephropathy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322181128027485081, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, authorId=1322181127830352790, language=CN, stringName=李凝旭, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=华中科技大学同济医学院附属梨园医院肾病内科，武汉　430077, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322181127402533773, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, xref=null, ext=[AuthorCompanyExt(id=1322181127410922382, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, companyId=1322181127402533773, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Nephropathy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China), AuthorCompanyExt(id=1322181127415116687, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322181126488175498, companyId=1322181127402533773, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=华中科技大学同济医学院附属梨园医院肾病内科，武汉　430077)])])]

唐明娟, 李凝旭

作者信息

华中科技大学同济医学院附属梨园医院肾病内科，武汉　430077

通讯作者:

李凝旭，女，副主任医师，硕士生导师，研究方向：糖尿病肾病治疗研究。E-mail：liningxu@hust.edu.cn。

作者简介:

唐明娟，女，硕士研究生，研究方向：糖尿病肾病治疗研究。E-mail：m201876025@hust.edu.cn。

Research progress on the renal protective mechanisms of sodium-dependent glucose transporters 2 inhibitors except hypoglycemic effect

Ming-juan TANG, Ning-xu LI

Affiliations

Department of Nephropathy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China

出版时间: 2021-07-30

文章导航

摘要

收起

钠-葡萄糖协同转运蛋白2（sodium-dependent glucose transporters 2，SGLT2）抑制剂（SGLT2 inhibition，SGLT2i）是全新机制的降糖药物，它与肾小管葡萄糖重吸收相关。在大规模随机对照试验中，SGLT2i在肾脏保护方面可降低终末期肾病、肾透析、肾移植等事件风险，对于肾脏的保护作用远远超出了其对于血糖的影响。考虑到其他具有更强的降糖效果的药物并未出现类似的获益，SGLT2i显然具有降糖外的肾脏保护机制，这也是目前临床治疗和研究的热点，本文综述其相关作用与机制。

关键词

钠-葡萄糖协同转运蛋白2 / 钠-葡萄糖协同转运蛋白2抑制剂 / 糖尿病肾病 / 管球反馈 / 超滤 / 蛋白尿 / 炎症 / 纤维化

Abstract

收起

Sodium-dependent glucose transporters 2 inhibitors (SGLT2i), as a new hypoglycemic drugs, are associated with renal tubular reabsorption of glucose. In several large-scale clinical randomized controlled trials, SGLT2i decreased the incidence of end-stage renal disease and the demand for dialysis or transplantation due to kidney disease. Its renoprotective effect is far beyond its hypoglycemic effect. Considering that other drugs with stronger hypoglycemic effect have not gained similar benefits, SGLT2i obviously has a renal protective mechanism outside hypoglycemic effect, becoming the hot spot for clinical treatment and research field at present. In this paper, the relevant functions and mechanisms are reviewed.

Key words

sodium-dependent glucose transporters 2 / SGLT2 inhibition / diabetic nephropathy / tubologlomerular feedback / hyperfiltration / albuminuria / inflammation / fibrosis

引用本文

唐明娟, 李凝旭. 钠-葡萄糖协同转运蛋白2抑制剂降糖作用外肾脏保护机制研究进展. 中国新药杂志, 2021 , 30 (14) : 1289 -1295 .

Ming-juan TANG, Ning-xu LI. Research progress on the renal protective mechanisms of sodium-dependent glucose transporters 2 inhibitors except hypoglycemic effect[J]. Chinese Journal of New Drugs, 2021 , 30 (14) : 1289 -1295 .

基金

收起

国家自然科学基金资助项目(81673657)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

AFKARIAN M, ZELNICK LR, HALL YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014[J]. JAMA, 2016, 316(6): 602-610.

[2]

HEDIGER MA, COADY MJ, IKEDA TS, et al. Expression cloning and cDNA sequencing of the Na⁺/glucose co-transporter[J]. Nature, 1987, 330(6146): 379-381.

[3]

KANAI Y, LEE WS, YOU G, et al. The human kidney low affinity Na⁺/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose[J]. J Clin Invest, 1994, 93(1): 397-404.

[4]

WRIGHT EM, LOO DDF, HIRAYAMA BA. Biology of human sodium glucose transporters[J]. Physiol Rev, 2011, 91(2): 733-794.

[5]

CHEN J, WILLIAMS S, HO S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members[J]. Diabetes Ther, 2010, 1(2): 57-92.

[6]

VRHOVAC I, BALEN EROR D, KLESSEN D, et al. Localizations of Na⁺-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart[J]. Pflugers Arch-Eur J Physiol, 2015, 467(9): 1881-1898.

[7]

DEFRONZO RA, NORTON L, ABDUL-GHANI M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition[J]. Nat Rev Nephrol, 2017, 13(1): 11-26.

[8]

HUMMEL CS, LU C, LOO DD, et al. Glucose transport by human renal Na⁺/D-glucose cotransporters SGLT1 and SGLT2[J]. Am J Physiol Cell Physiol, 2011, 300(1): C14-C21.

[9]

RIEG T, MASUDA T, GERASIMOVA M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia[J]. Am J Physiol Ren Physiol, 2014, 306(2): F188-F193.

[10]

RIEG T, VALLON V. Development of SGLT1 and SGLT2 inhibitors[J]. Diabetologia, 2018, 61(10): 2079-2086.

[11]

FARBER SJ, BERGER EY, EARLE DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose[J]. J Clin Invest, 1951, 30(2): 125-129.

[12]

MOGENSEN CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects[J]. Scand J Clin Lab Invest, 1971, 28(1): 101-109.

[13]

VALLON V, ROSE M, GERASIMOVA M, et al. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus[J]. Am J Physiol Ren Physiol, 2013, 304(2): F156-F167.

[14]

VALLON V, GERASIMOVA M, ROSE MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice[J]. Am J Physiol Ren Physiol, 2014, 306(2): 194-204.

[15]

WANG XX, LUO Y, WANG D, et al. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice[J]. J Biol Chem, 2017, 292(29): 12018-12024.

[16]

ROSSETTI L, SHULMAN GI, ZAWALICH W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats[J]. J Clin Invest, 1987, 80(4): 1037-1044.

[17]

KAHN BB, SHULMAN GI, DEFRONZO RA, et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression[J]. J Clin Invest, 1991, 87(2): 561-570.

[18]

CHERNEY DZ, ODUTAYO A, ARONSON R, et al. Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review topic of the week[J]. J Am Coll Cardiol, 2019, 74(20): 2511-2524.

[19]

NEUEN BL, YOUNG T, HEERSPINK HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis[J]. Lancet Diabetes Endocrinol, 2019, 7(11): 845-854.

[20]

THOMSON SC, BLANTZ RC. Glomerulotubular balance, tubuloglomerular feedback, and salt homeostasis[J]. J Am Soc Nephrol, 2008, 19(12): 2272-2275.

[21]

FAULHABER-WALTER R, CHEN L, OPPERMANN M, et al. Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury[J]. J Am Soc Nephrol, 2008, 19(4): 722-730.

[22]

BRENNER PDBM. Hemodynamically mediated glomerular injury and the progressive nature of kidney disease[J]. Kidney Int, 1983, 23(4): 647-655.

[23]

BRADY JA, HALLOW KM. Model-based evaluation of proximal sodium reabsorption through SGLT2 in health and diabetes and the effect of inhibition with canagliflozin[J]. J Clin Pharmacol, 2018, 58(3): 377-385.

[24]

THOMSON SC, RIEG T, MIRACLE C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat[J]. Am J Physiol Regul Integr Comp Physiol, 2012, 302(1): R75-R83.

[25]

CHERNEY DZI, PERKINS BA, SOLEYMANLOU N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus[J]. Circulation, 2014, 129(5): 587-597.

[26]

XU L, LI Y, LANG J, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis[J]. PeerJ, 2017, 5(9): e3405.

[27]

CHERNEY DZI, ZINMAN B, INZUCCHI SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2017, 5(8): 610-621.

[28]

SEIDU S, KUNUTSOR SK, COS X, et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis[J]. Prim Care Diabetes, 2018, 12(3): 265-283.

[29]

SUGIYAMA S, JINNOUCHI H, YOSHIDA A, et al. Renoprotective effects of additional SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and chronic kidney disease stages 3b-4: a real world report from A Japanese specialized diabetes care center[J]. J Clin Med Res, 2019, 11(4): 267-274.

[30]

TAKEUCHI M, OGURA M, MINOURA T, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus other classes of glucose-lowering medications on renal outcome in type 2 diabetes[J]. Mayo Clin Proc, 2020, 95(2): 265-273.

[31]

CHERNEY D, LUND SS, PERKINS BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes[J]. Diabetologia, 2016, 59(9): 1860-1870.

[32]

ABDEL-WAHAB AF, BAMAGOUS GA, AL-HARIZY RM, et al. Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy[J]. Biomed Pharmacother, 2018, 103: 59-66.

[33]

CHERNEY D, PERKINS BA, LYTVYN Y, et al. The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome[J]. PLoS One, 2017, 12(10): e0186910.

[34]

YOUNIS F, LEOR J, ABASSI Z, et al. Beneficial effect of the SGLT2 inhibitor empagliflozin on glucose homeostasis and cardiovascular parameters in the Cohen rosenthal diabetic hypertensive (CRDH) rat[J]. J Cardiovasc Pharmacol Ther, 2018, 23(4): 358-371

[35]

WANG XX, LEVI J, LUO Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice[J]. J Biol Chem, 2017, 292(13): 5335-5348.

[36]

TANG L, WU Y, TIAN M, et al. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes[J]. Am J Physiol Endocrinol Metab, 2017, 313(5): e563-e576.

[37]

BIRNBAUM Y, BAJAJ M, YANG HC, et al. Combined SGLT2 and DPP₄ inhibition reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic nephropathy in mice with type 2 diabetes[J]. Cardiovasc Drugs Ther, 2018, 32(2): 135-145.

[38]

YAO D, WANG SY, WANG M, et al. Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-κB signaling pathway[J]. Mol Med Rep, 2018, 18(4): 3625-3630.

[39]

HEERSPINK HJL, PERCO P, MULDER S, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J]. Diabetologia, 2019, 62(7): 1154-1166.

[40]

INOUE MK, MATSUNAGA Y, NAKATSU Y, et al. Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice[J]. Diabetol Metab Syndr, 2019, 11(1): 57.

[41]

PANCHAPAKESAN U, PEGG K, GROSS S, et al. Effects of SGLT2 inhibition in human kidney proximal tubular cells: renoprotection in diabetic nephropathy?[J]. PLoS One, 2013, 8(2): e54442.

[42]

OJIMA A, MATSUI T, NISHINO Y, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis[J]. Horm Metab Res, 2015, 47(9): 686-692.

[43]

HUANG F, ZHAO Y, WANG Q, et al. Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1/TGFβ1 signaling[J]. Front Endocrinol (Lausanne), 2019, 10: 441.

[44]

TANG H, ZHANG X, ZHANG J, et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials[J]. Diabetologia, 2016, 59(12): 2546-2551.

[45]

ZHAO Y, XU L, TIAN D, et al. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a Meta-analysis of randomized controlled trials[J]. Diabetes Obes Metab, 2018, 20(2): 458-462.

[46]

NOVIKOV A, FU YL, HUANG W, et al. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1[J]. Am J Physiol Ren Physiol, 2019, 316(1): F173-F185.

[47]

PERRY RJ, RABIN-COURT A, SONG JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats[J]. Nat Commun, 2019, 10(1): 548.

[48]

WIVIOTT SD, RAZ I, BONACA MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med, 2019, 380(4): 347-357.

[49]

PERKOVIC V, JARDINE MJ, NEAL B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J]. N Engl J Med, 2019, 380(24): 2295-2306.

[50]

HINNEN D. Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes[J]. Ther Adv Endocrinol Metab, 2015, 6(3): 92-102.

[51]

ESTEBAN-JIMÉNEZ O, NAVARRO-PEMÁN C, URIETA-GONZÁLEZ L. Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database[J]. Semergen, 2018, 44(1): 23-29.

[52]

BERSOFF-MATCHA SJ, CHAMBERLAIN C, CAO C, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases[J]. Ann Intern Med, 2019, 170(11): 764-769.

[53]

谢少斐, 张凤逸, 邹珊, 等. 已上市钠-葡萄糖协同转运蛋白2抑制剂临床药动学特点比较[J]. 中国现代应用药学, 2016, 33(4): 517-520.

[54]

WANG T, PATEL SM, HICKMAN A, et al. SGLT2 inhibitors and the risk of hospitalization for Fournier's gangrene: a nested case-control study[J]. Diabetes Ther, 2020, 11(3): 711-723.

2021年第30卷第14期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-07-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-12-04

基金

国家自然科学基金资助项目(81673657)

作者信息

华中科技大学同济医学院附属梨园医院肾病内科，武汉　430077

通讯作者:

李凝旭，女，副主任医师，硕士生导师，研究方向：糖尿病肾病治疗研究。E-mail：liningxu@hust.edu.cn。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322181126488175498

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT